Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease

Genetics in Medicine

Volumn 12, Issue 4 SUPPL., 2010, Pages

  Skeehan, Katie ^a   Heaney, Christopher ^a   Cook Deegan, Robert ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Alzheimer disease; Athena diagnostics; Genetic testing; Intellectual property; Patents

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BRCA1 PROTEIN; BRCA2 PROTEIN; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOMICS; GENOTYPE; HEALTH INSURANCE; HUMAN; LICENSING; NEUROPATHOLOGY; REIMBURSEMENT; REVIEW; RISK ASSESSMENT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; GENETIC TESTING; HUMANS; LICENSURE; PATENTS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PRESENILIN-1; PRESENILIN-2;

EID: 77951457863     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181d5a68e     Document Type: Review

References (58)

1. Alzheimer's Association. Alzheimer's disease facts and figures 2007: a statistical abstract of U.S. data on Alzheimer's disease. Available at: http://alz.org/national/documents/Report-2007FactsAndFigures.pdf. Accessed July 16, 2007.
2. Beecham GW, Martin ER, Li Y-J, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009;84:35-43.
3. Hayden EC. Alzheimer's tests under fire. Nature 2008;455:1155.
4. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997; 277:832-836.
5. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
6. Schutte DL, Holston EC. Chronic dementing conditions, genomics, and new opportunities for nursing interventions. J Nurs Scholarsh 2006;38:328-334.
7. Bird TD. Genetic aspects of Alzheimer disease. Genet Med 2008;10:231-239.
8. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes? Hum Mol Genet 2004;13(Review Issue 1):R135-R141.
9. Strobel G. What is early-onset familial Alzheimer disease (EFAD)? 9 April 2007. Available at: http://www.alzforum.org/eFAD/overview/essay2/default.asp. Accessed July 16, 2007.
10. Raux G, Guyant-Marechal L, Martin C, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet 2005;42:3.
11. Glenner G, Wong C. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890. (Pubitemid 14104991)
12. Glenner G, Wong C. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Com-mun 1984;122:1131-1135.
13. Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706. (Pubitemid 21912142)
14. Alzheimer Disease and Frontotemporal Dementia Mutation Database. Available at: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=1&ML= 1&page=MutByGene. Accessed November 5, 2008.
15. Blacker D. New insights into genetic aspects of Alzheimer's disease. Postgrad Med 2000;108:119-129.
16. Pollen D. Hannah's heirs: the quest for the genetic origins of Alzheimer's disease. New York: Oxford University Press, 1993.
17. Roses AD. Apoliopoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996;47:387-400.
18. Ashford J. APOE genotype effects on Alzheimer's disease onset and epidemiology. JMolNeurosci 2004;23:157-165.
19. Farrer L, Cupples L, Haines J, et al. Effects of age, sex, and ethnicity on the association between Apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997 1997;278:1349-1356.
20. In Re Bilski, 545 F. 3d 943 (Fed Cir. 2008).
21. Tanzi RE, Parson AB. Decoding darkness: the search for the genetic causes of Alzheimer's disease. Cambridge: Perseus, 2000.
22. Winik LW, Chen D, Greco P. Intelligence report: a home test for Alzheimer's. Parade. March 30, 2008.
23. Lei H-H. Smart Genetics shuts its doors. Available at: http://www.eyeondna. com/2008/10/06/smart-genetics-shuts-its-doors/. Accessed November 12, 2009.
24. Genetic testers Smart Genetics closes. Phila Bus JOctober 3, 2008.
25. Leonard D. Patents and licensing fundamentals and the nature of the access problem. Secretary's Advisory Committee on Genetics, Health, and Society. Available at: http://oba.od.nih.gov/oba/SACGHS/meetings/June2006/Leonard3.pdf. Accessed January 14, 2009.
26. Athena Diagnostics. Test catalog. Available at: http://www. athenadiagnostics. com/content/test-catalog/. Accessed November 14, 2008
27. Smart Genetics announces plans to launch a new Alzheimer's risk assessment service; preeminent team of medical advisers helps guide new service offering. PR Newswire. February 7, 2008.
28. Flam F. Genetic test for Alzheimer's divides experts. Philadelphia Inquirer. March 11, 2008: A1.
29. Graceful Earth, Inc. Available at: http://www.gracefulearth.com/index. asp?PageAction=VIEWPROD&ProdID=3&HS=1. Accessed November 5, 2008.
30. Meeting transcript. Secretary's Advisory Committee on Genetics, Health, and Society. Available at: http://oba.od.nih.gov/oba/sacghs/meetings/March2004/ FullDay030104.pdf. Accessed January 16, 2009.
31. Risner M, Saunders A, Altman J, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:9.
32. Roses AD, Saunders A, Huang Y, Strum J, Weisgraber K, Mahley R. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Phar-macogenomics J 2007;7:10-28.
33. Roses AD. Commentary on 'A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium meeting report.' An impending prevention clinical trial for Alzheimer's disease: roadmaps and realities. Alzheimers Dement 2008;4:164-166.
34. Aetna. Clinical policy bulletin: Alzheimer's disease: diagnosis, number:0349. Available at: http://www.aetna.com/cpb/medical/data/300-399/0349. html. Accessed November 14, 2008.
35. Kaiser Permanente. ApolipoproteinE-4 genetic (DNA) test. Available athttps://members.kaiserpermanente.org/kpweb/healthency.do?hwid=hw135696& sectionId=hw135696-sec&contextId=hw136623. Accessed November 12,2009.
36. CIGNA HealthCare. CIGNA HealthCare coverage position, coverage position number: 0392. Available at: http://www.cigna.com/customer-care/healthcare- professional/coverage-positions/medical/mm-0392-coveragepositioncriteria- genetic-testing-alzheimers.pdf. Accessed November 14, 2008.
37. McConnell LM, Koenig B, Greely H, Raffin T; Members of the Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics, and Society. Genetic testing and Alzheimer disease: recommendations of the Stanford Program in Genomics, Ethics, and Society. Genet Test 1999;3:3-12.
38. Lovestone S. The genetics of Alzheimer's disease\new opportunities and new challenges. Int J Geriatr Psychiatry 1995;10:1-7.
39. American College of Medical Genetics/American Society of Hum Genet Working Group on ApoE and Alzheimer disease. Statement on use of apolipoproteinE testing for Alzheimer disease. JAMA 1995;274:1627-1629.
40. Brodaty H, Conneally M, Gauthier S, Jennings C, Lennox A, Lovestone S. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis Assoc Disord 1995;9:182-187.
41. Relkin N, Kwon Y, Tsai J, Gandy S. The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Ann N YAcadSci 1996;802:149-176.
42. McConnell L, Koenig B, Greely H, Raffin T, Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics, and Society. Genetic testing and Alzheimer disease: has the time come? Nat Med 1998;4:757-759.
43. Mayeux R, Saunders A, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338: 506-511. (Pubitemid 28103134)
44. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361:245-254.
45. Santacruz KS, Swagerty D. Early diagnosis of dementia. Am Fam Physician 2001;63:703-713.
46. Liddell MB, Lovestone S, Owen MJ. Genetic risk of Azlehimer's disease: advising relatives. Br J Psychiatry 2001:7-11. (Pubitemid 32055638)
47. Gosline A. Genome scans go deep into your DNA. Los Angeles Times April 14, 2008.
48. Navigenics. Our policy regarding gene patents. Available at: http://www.navigenics.com/visitor/what-we-offer/our-policies/gene-patents/. Accessed November 12, 2009.
49. Cho M, Illangasekare S, Weaver M, Leonard D, Merz J. Effects of patents and licenses on provision of clinical genetic testing services. J Mol Diagn 2003;5:3-8.
50. Athena Diagnostics. About Athena Diagnostics. Available at: http://www.athenadiagnostics.com/content/about/. Accessed November 14, 2008.
51. Cordes N. Genetic mapping more hype than help? Looking behind the cost and business of mapping your DNA destiny. Available at: http://www.cbsnews.com/ stories/2008/05/07/eveningnews/main4078733.shtml. Accessed November 13, 2009.
52. Rubin R. Want to know if you're destined for Alzheimer's? Genetic test measures risk factor, but then what do you do? USA Today. March 6, 2008;Life: 5D.
53. Roberts JS, Cupples LA, Relkin N, Whitehouse P, Green RC; REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol 2005;18:250-255.
54. Couzin J. Once shunned, test for Alzheimer's risk headed to market. Science. February 22 2008;319:1022-1023.
55. Lapidus S. Interpreting the genome (video). Technology Review. Available at: http://www.technologyreview.com/Video/?vid+187. Accessed January 21, 2009.
56. Pinker S. My genome, my self. New York Times Magazine. 2009.
57. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff 2005;24:483-490.
58. Coon K, Myers A, Craig D, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007;68:613-618. (Pubitemid 46663046)